The management of osteoporosis in children
- PMID: 27125514
- DOI: 10.1007/s00198-016-3515-9
The management of osteoporosis in children
Abstract
This article reviews the manifestations and risk factors associated with osteoporosis in childhood, the definition of osteoporosis and recommendations for monitoring and prevention. As well, this article discusses when a child should be considered a candidate for osteoporosis therapy, which agents should be prescribed, duration of therapy and side effects. There has been significant progress in our understanding of risk factors and the natural history of osteoporosis in children over the past number of years. This knowledge has fostered the development of logical approaches to the diagnosis, monitoring, and optimal timing of osteoporosis intervention in this setting. Current management strategies are predicated upon monitoring at-risk children to identify and then treat earlier rather than later signs of osteoporosis in those with limited potential for spontaneous recovery. On the other hand, trials addressing the prevention of the first-ever fracture are still needed for children who have both a high likelihood of developing fractures and less potential for recovery. This review focuses on the evidence that shapes the current approach to diagnosis, monitoring, and treatment of osteoporosis in childhood, with emphasis on the key pediatric-specific biological principles that are pivotal to the overall approach and on the main questions with which clinicians struggle on a daily basis. The scope of this article is to review the manifestations of and risk factors for primary and secondary osteoporosis in children, to discuss the definition of pediatric osteoporosis, and to summarize recommendations for monitoring and prevention of bone fragility. As well, this article reviews when a child is a candidate for osteoporosis therapy, which agents and doses should be prescribed, the duration of therapy, how the response to therapy is adjudicated, and the short- and long-term side effects. With this information, the bone health clinician will be poised to diagnose osteoporosis in children and to identify when children need osteoporosis therapy and the clinical outcomes that gauge efficacy and safety of treatment.
Keywords: Bisphosphonates; Bone density; Bone fragility; Denosumab; Diagnosis; Monitoring; Osteoporosis; Treatment; Vertebral fractures.
Similar articles
-
Osteoporosis in childhood.Curr Opin Rheumatol. 2017 Sep;29(5):535-546. doi: 10.1097/BOR.0000000000000423. Curr Opin Rheumatol. 2017. PMID: 28582319 Review.
-
Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.Curr Osteoporos Rep. 2017 Aug;15(4):271-282. doi: 10.1007/s11914-017-0371-2. Curr Osteoporos Rep. 2017. PMID: 28620868 Review.
-
Diagnosis and treatment of pediatric osteoporosis.Curr Opin Endocrinol Diabetes Obes. 2014 Dec;21(6):454-60. doi: 10.1097/MED.0000000000000106. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 25232753 Review.
-
Part I: Which Child with a Chronic Disease Needs Bone Health Monitoring?Curr Osteoporos Rep. 2021 Jun;19(3):278-288. doi: 10.1007/s11914-021-00667-x. Epub 2021 Jul 10. Curr Osteoporos Rep. 2021. PMID: 34245406 Review.
-
Part 2: When Should Bisphosphonates Be Used in Children with Chronic Illness Osteoporosis?Curr Osteoporos Rep. 2021 Jun;19(3):289-297. doi: 10.1007/s11914-021-00672-0. Epub 2021 Jun 19. Curr Osteoporos Rep. 2021. PMID: 34146247 Review.
Cited by
-
Case Report and Literature Review: Bisphosphonate, Sirolimus, and Atenolol Treatment in a 4-Year-Old Child Diagnosed with Gorham-Stout Disease.Pharmaceuticals (Basel). 2023 Oct 23;16(10):1504. doi: 10.3390/ph16101504. Pharmaceuticals (Basel). 2023. PMID: 37895975 Free PMC article.
-
Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta.Osteoporos Int. 2017 Jul;28(7):2095-2101. doi: 10.1007/s00198-017-4031-2. Epub 2017 Apr 4. Osteoporos Int. 2017. PMID: 28378289
-
Bone health in childhood and adolescence: an overview on dual-energy X-ray absorptiometry scanning, fracture surveillance and bisphosphonate therapy for low-middle-income countries.Front Endocrinol (Lausanne). 2023 Apr 17;14:1082413. doi: 10.3389/fendo.2023.1082413. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37139332 Free PMC article. Review.
-
Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.Lancet Neurol. 2018 Apr;17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3. Lancet Neurol. 2018. PMID: 29395990 Free PMC article. Review.
-
Diagnosis and Management of Osteoporosis in Children and Adolescents.Ewha Med J. 2023 Oct;46(4):e18. doi: 10.12771/emj.2023.e18. Epub 2023 Oct 31. Ewha Med J. 2023. PMID: 40703945 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous